vorinostat has been researched along with Bone Loss, Osteoclastic in 5 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Vorinostat-treated and control mice without tumors were also examined." | 5.36 | The histone deacetylase inhibitor, vorinostat, reduces tumor growth at the metastatic bone site and associated osteolysis, but promotes normal bone loss. ( Akech, J; Bedard, K; Dhillon, RJ; Hussain, S; Li, X; Lian, JB; McGee-Lawrence, ME; Pratap, J; Stein, GS; Stein, JL; Szabo, G; van Wijnen, AJ; Westendorf, JJ; Wixted, JJ, 2010) |
| "Vorinostat-treated and control mice without tumors were also examined." | 1.36 | The histone deacetylase inhibitor, vorinostat, reduces tumor growth at the metastatic bone site and associated osteolysis, but promotes normal bone loss. ( Akech, J; Bedard, K; Dhillon, RJ; Hussain, S; Li, X; Lian, JB; McGee-Lawrence, ME; Pratap, J; Stein, GS; Stein, JL; Szabo, G; van Wijnen, AJ; Westendorf, JJ; Wixted, JJ, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| McGee-Lawrence, ME | 3 |
| Westendorf, JJ | 3 |
| Xu, S | 1 |
| De Veirman, K | 1 |
| Vanderkerken, K | 1 |
| Van Riet, I | 1 |
| Pratap, J | 1 |
| Akech, J | 1 |
| Wixted, JJ | 1 |
| Szabo, G | 1 |
| Hussain, S | 1 |
| Li, X | 2 |
| Bedard, K | 1 |
| Dhillon, RJ | 1 |
| van Wijnen, AJ | 1 |
| Stein, JL | 1 |
| Stein, GS | 2 |
| Lian, JB | 2 |
| McCleary-Wheeler, AL | 1 |
| Secreto, FJ | 1 |
| Razidlo, DF | 1 |
| Zhang, M | 1 |
| Stensgard, BA | 1 |
| Cantley, MD | 1 |
| Fairlie, DP | 1 |
| Bartold, PM | 1 |
| Rainsford, KD | 1 |
| Le, GT | 1 |
| Lucke, AJ | 1 |
| Holding, CA | 1 |
| Haynes, DR | 1 |
5 other studies available for vorinostat and Bone Loss, Osteoclastic
| Article | Year |
|---|---|
Reply to vorinostat induced bone loss in mice.
Topics: Animals; Bone Resorption; Cell Differentiation; Humans; Hydroxamic Acids; Male; Osteoblasts; Vorinos | 2013 |
Vorinostat-induced bone loss might be related to drug toxicity.
Topics: Animals; Bone Resorption; Drug Administration Schedule; Gene Expression Regulation; Histone Deacetyl | 2013 |
The histone deacetylase inhibitor, vorinostat, reduces tumor growth at the metastatic bone site and associated osteolysis, but promotes normal bone loss.
Topics: Animals; Bone and Bones; Bone Neoplasms; Bone Resorption; Cell Line, Tumor; Cell Proliferation; Extr | 2010 |
Suberoylanilide hydroxamic acid (SAHA; vorinostat) causes bone loss by inhibiting immature osteoblasts.
Topics: Acetylation; Animals; Biomarkers; Body Weight; Bone Marrow Cells; Bone Remodeling; Bone Resorption; | 2011 |
Inhibitors of histone deacetylases in class I and class II suppress human osteoclasts in vitro.
Topics: Acid Phosphatase; Benzamides; Bone Resorption; Cell Differentiation; Cells, Cultured; Cytokine TWEAK | 2011 |